Immunoprecise Financial Statements From 2010 to 2022

IPA -  USA Stock  

USD 5.30  0.15  2.75%

Immunoprecise Antibodies financial statements provide useful quarterly and yearly information to potential Immunoprecise Antibodies investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Immunoprecise Antibodies financial statements helps investors assess Immunoprecise Antibodies' valuation, profitability, and current liquidity needs.
We have found seventy available fundamental trends for Immunoprecise Antibodies, which can be analyzed and compared to other ratios and to its competitors. Make sure you confirm all of Immunoprecise Antibodies regular market performance against the performance between 2010 and 2022 to make sure the company can sustain itself down the road.
Immunoprecise Antibodies Tangible Asset Value is projected to increase significantly based on the last few years of reporting. The past year's Tangible Asset Value was at 61.09 Million. The current year Working Capital is expected to grow to about 53.1 M, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are forecasted to decline to (1.8 M).
  
Refresh
Check Immunoprecise Antibodies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunoprecise main balance sheet or income statement drivers, such as Cost of Revenue of 7.3 M, Gross Profit of 11.8 M or Interest Expense of 596.1 K, as well as many exotic indicators such as Asset Turnover of 0.36, Book Value per Share of 3.25 or Current Ratio of 9.98. Immunoprecise financial statements analysis is a perfect complement when working with Immunoprecise Antibodies Valuation or Volatility modules. It can also supplement various Immunoprecise Antibodies Technical models. Please see the analysis of Immunoprecise Antibodies Correlation against competitors.

Immunoprecise Antibodies Revenues

19.12 Million

Share

Immunoprecise Antibodies Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets64.2 M77 M37.8 M
Increasing
Slightly volatile
Cash and Equivalents51.9 M48.1 M15 M
Increasing
Slightly volatile
Investments129 K127.7 K100 K
Increasing
Slightly volatile
Investments Non Current129 K127.7 K100 K
Increasing
Slightly volatile
Deferred Revenue1.3 M1.3 M899.8 K
Increasing
Slightly volatile
Property Plant and Equipment Net4.1 M4.6 M2.4 M
Increasing
Slightly volatile
Inventory1.3 M1.4 M913.6 K
Increasing
Slightly volatile
Tax Assets464.8 K564.6 K184.6 K
Increasing
Slightly volatile
Trade and Non Trade ReceivablesM4.2 M2.5 M
Increasing
Slightly volatile
Trade and Non Trade Payables3.1 M3.5 MM
Increasing
Slightly volatile
Goodwill and Intangible Assets13.3 M12.5 M16.8 M
Decreasing
Slightly volatile
Total Liabilities9.3 MM10.3 M
Decreasing
Stable
Shareholders Equity51.8 M65.5 M27.1 M
Increasing
Slightly volatile
Current Assets60.6 M56.2 M19.3 M
Increasing
Slightly volatile
Assets Non Current16.7 M16.3 M19.2 M
Decreasing
Slightly volatile
Current Liabilities5.9 M5.5 M6.9 M
Decreasing
Slightly volatile
Liabilities Non Current4.6 M4.6 M3.5 M
Increasing
Slightly volatile
Tax Liabilities1.7 M1.8 MM
Decreasing
Slightly volatile
Total Debt4.2 MM3.3 M
Increasing
Slightly volatile
Debt Current910.8 K887.4 K2.4 M
Decreasing
Slightly volatile
Debt Non Current2.3 M2.8 M781.2 K
Increasing
Slightly volatile
Shareholders Equity USD57.4 M53.2 M22.2 M
Increasing
Slightly volatile
Cash and Equivalents USD42.2 M39.1 M11.9 M
Increasing
Slightly volatile
Total Debt USD3.3 M3.2 M2.5 M
Increasing
Slightly volatile

Immunoprecise Antibodies Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues19.1 M20.6 M13.1 M
Increasing
Slightly volatile
Cost of Revenue7.3 M7.3 MM
Increasing
Slightly volatile
Selling General and Administrative Expense8.7 M9.2 M6.4 M
Increasing
Slightly volatile
Research and Development Expense2.4 M2.3 M885.5 K
Increasing
Slightly volatile
Operating Expenses19.3 M21.2 M13.4 M
Increasing
Slightly volatile
Interest Expense596.1 K594.5 K459 K
Increasing
Slightly volatile
Income Tax Expense1.7 M1.5 M327.5 K
Increasing
Slightly volatile
Weighted Average Shares18.2 M18.9 M13.9 M
Increasing
Slightly volatile
Weighted Average Shares Diluted18.2 M18.9 M13.9 M
Increasing
Slightly volatile
Revenues USD15.1 M16.7 M10 M
Increasing
Slightly volatile
Gross Profit11.8 M13.3 M7.1 M
Increasing
Slightly volatile

Immunoprecise Antibodies Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow from Financing53.8 M49.9 M17.8 M
Increasing
Slightly volatile
Issuance Purchase of Equity Shares54.8 M50.8 M18.4 M
Increasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents50 M46.4 M13 M
Increasing
Slightly volatile
Share Based Compensation2.6 M3.2 M1.5 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion4.7 M4.7 M3.6 M
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Gross Margin0.720.740.5416
Increasing
Slightly volatile
Asset Turnover0.360.340.4719
Decreasing
Slightly volatile
Sales per Share0.971.020.7263
Increasing
Slightly volatile
Price to Sales Ratio9.889.9410.8669
Decreasing
Slightly volatile
Price to Book Value3.193.213.5092
Decreasing
Slightly volatile
Debt to Equity Ratio0.160.160.4986
Decreasing
Slightly volatile
Current Ratio9.989.252.9956
Increasing
Slightly volatile
Book Value per Share3.253.971.9037
Increasing
Slightly volatile
Tangible Assets Book Value per Share4.03.711.4748
Increasing
Slightly volatile

Immunoprecise Antibodies Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Capitalization147.6 M148.5 M162.4 M
Decreasing
Slightly volatile
Enterprise Value138.9 M139.7 M152.8 M
Decreasing
Slightly volatile
Invested CapitalM10 M2.8 M
Increasing
Slightly volatile
Average Equity36.2 M40.3 M21.3 M
Increasing
Slightly volatile
Average Assets50 M54 M33 M
Increasing
Slightly volatile
Invested Capital Average8.2 M9.5 M4.1 M
Increasing
Slightly volatile
Tangible Asset Value65.9 M61.1 M21.9 M
Increasing
Slightly volatile
Working Capital53.1 M49.2 M12.1 M
Increasing
Slightly volatile

Immunoprecise Fundamental Market Drivers

Forward Price Earnings-13.59
Shares Short Prior Month282.2k
Average Daily Volume Last 10 Day18.56k
Average Daily Volume In Three Month30.76k
Date Short Interest29th of April 2022
Fifty Day Average5.14
Two Hundred Day Average5.71

About Immunoprecise Antibodies Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Immunoprecise Antibodies income statement, its balance sheet, and the statement of cash flows. Immunoprecise Antibodies investors use historical funamental indicators, such as Immunoprecise Antibodies's revenue or net income, to determine how well the company is positioned to perform in the future. Although Immunoprecise Antibodies investors may use each financial statement separately, they are all related. The changes in Immunoprecise Antibodies's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Immunoprecise Antibodies's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Immunoprecise Antibodies Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Immunoprecise Antibodies. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Deferred Revenue1.3 M1.3 M
Cost of Revenue7.3 M7.3 M
Revenues20.6 M19.1 M
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing B cell sorting, screening, and sequencing custom, immune, and naive phage display production and screening transgenic animals and multi-species antibody discovery bi-specific, tri-specific, VHH, and VNAR antibody manufacturing DNA cloning, protein and antibody downstream processing antibody characterization on label-free biosensors and antibody engineering transient and stable cell line generation antibody optimization and humanization hybridoma production with multiplexed, high-throughput screening, and clone-picking and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

Immunoprecise Antibodies Investors Sentiment

The influence of Immunoprecise Antibodies' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Immunoprecise. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Immunoprecise Antibodies Implied Volatility

    
  284.64  
Immunoprecise Antibodies' implied volatility exposes the market's sentiment of Immunoprecise Antibodies stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Immunoprecise Antibodies' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Immunoprecise Antibodies stock will not fluctuate a lot when Immunoprecise Antibodies' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immunoprecise Antibodies in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immunoprecise Antibodies' short interest history, or implied volatility extrapolated from Immunoprecise Antibodies options trading.

Current Sentiment - IPA

Immunoprecise Antibodies Investor Sentiment

Macroaxis portfolio users are indifferent in their judgment towards investing in Immunoprecise Antibodies. What is your judgment towards investing in Immunoprecise Antibodies? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immunoprecise Antibodies using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Immunoprecise Antibodies Correlation against competitors. Note that the Immunoprecise Antibodies information on this page should be used as a complementary analysis to other Immunoprecise Antibodies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Complementary Tools for Immunoprecise Stock analysis

When running Immunoprecise Antibodies price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Is Immunoprecise Antibodies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine Immunoprecise Antibodies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.